To view this email as a web page, click here

Today's Rundown

Featured Story

Sanofi, Translate Bio start seasonal mRNA flu vaccine trial, gaining early lead over Moderna and Pfizer

Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show mRNA vaccines are as good or better at preventing flu than existing technologies. 

read more

Top Stories

Blackstone, Cellex and Intellia form $250M CAR-T startup

Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics have teamed to create a CAR-T therapy startup. The biotech begins life with $250 million from Blackstone, universal CAR-T platforms from Cellex and CRISPR/Cas9 genome editing technology from Intellia.

read more

Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC

After grabbing government grants to develop its polyclonal antibody treatment for COVID-19, SAB Biotherapeutics is going public through a $118 million SPAC merger. The proceeds will bankroll a pipeline of treatments for various diseases that are produced by and extracted from genetically modified cows. 

read more

Sponsored: Addressing Roadblocks in Decentralized Clinical Trials

In a recent virtual roundtable discussion, industry experts shared their insight on the challenges faced in implementing decentralized trials and how to address them.

read more

TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding

TRexBio is far from extinction as the discovery-stage biotech refuels with a new CEO and CMO and picks up Big Pharma backers.

read more

Sponsored: Culture Drives Employee Engagement, Supports Business Growth

By refocusing company culture around the connection between employees and the rare disease community, Alexion has increased employee engagement and charted a new path for business success. Read more.

read more

Alchemab's new well-connected CEO will lead biotech on journey to address hard-to-treat diseases

After overseeing the $2.5 billion acquisition of Ra Pharmaceuticals last year, Douglas Treco, Ph.D., will lead Alchemab Therapeutics in its quest to develop therapies for hard-to-treat diseases. Treco is a well-connected executive with a history of raising biotechs up to be acquired by bigger pharmaceutical companies.

read more

Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials

Insilico Medicine netted $255 million in its third investment round—a big step up from the $37 million it raised in 2019—reflecting what it’s achieved in the intervening years.

read more

Resources

Whitepaper: How to Launch a Successful BYOD Strategy in Any Phase

For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink.

Paid Marketplace: Story of Success: Ashfield Healthcare Empowers Field Sales to Grow Market Share based on Data

Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products.

eBook: Improving Diversity and Inclusion in Clinical Trials

Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them.

Whitepaper: Closed Cell Processing System Benefits for Cell & Gene Therapy

Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process.

Guide: Your Guide to Overcome Inconsistent Clinical Data Standards

Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Events